Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04745234 · ClinicalTrials.gov registry record · Phase 2
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
A Phase 2 study of Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed, sponsored by Kyowa Kirin.
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 16
- Study locations
NCT04745234 is a Phase 2 study of Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed that is active but no longer recruiting, run by Kyowa Kirin. The registered enrollment target is 34 participants. The trial reports 16 study locations across 6 states.
The verdict
NCT04745234, a Phase 2 study of Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed, is active but no longer recruiting, sponsored by Kyowa Kirin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.
Conditions Studied
Interventions
- DRUG Mogamulizumab
Study Locations (16)
Other
- Hôpital Saint Louis - Paris
- Azienda Ospedaliera Città della Salute e della Scienza di Torino - Turin
- Hospital del Mar - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario De Salamanca - Salamanca
- Queen Elizabeth Hospital - Birmingham
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital - London
- The Christie NHS Foundation Trust - Manchester
California
- City of Hope National Medical Center - Duarte
- University of California Irvine - Irvine
- Stanford Cancer Center - Stanford
Louisiana
- Tulane University School of Medicine - New Orleans
New York
- New York Presbyterian Hospital - New York
Pennsylvania
- University of Pittsburgh School of Medicine - Pittsburgh
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2025-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04745234
The ClinicalTrials.gov registry entry for NCT04745234 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cutaneous T-Cell Lymphoma Refractory appearing as the primary indexed condition, and to 1 intervention - of which Mogamulizumab is the first listed.
NCT04745234 reports 16 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04745234 about?
NCT04745234 is a clinical study titled "Mogamulizumab Q4week Dosing in Participants With R/R CTCL". This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participa...
What is the current status of trial NCT04745234?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2021-08-16. Estimated completion is 2025-05.
What conditions does trial NCT04745234 study?
This clinical trial studies the following conditions: Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed.
What interventions are being tested in trial NCT04745234?
The interventions under investigation include: Mogamulizumab (DRUG).
Who is sponsoring clinical trial NCT04745234?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04745234 being conducted?
This trial has 16 study locations across California, Louisiana, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T-Cell Lymphoma Refractory
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Cutaneous T-Cell Lymphoma Refractory
All registered trials for this condition
Cutaneous T-Cell Lymphoma, Relapsed
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.